Factors affecting recurrence and survival in Stage IIA colon cancer patients.

Our study delves into the intricate interplay of risk factors and the strategic selection of adjuvant therapy, scrutinizing their influence on recurrence and survival outcomes in stage IIA (T3N0M0) colon cancer patients. The study examined the medical records of patients who underwent surgery for stage IIA colon cancer. Identification of stage IIA (pT3N0M0) colon cancer involved a comprehensive review of postoperative clinical records and histological reports. Parameters such as demographic data, tumor characteristics, MSI status, tumor locations, recurrence risk factors, preoperative CEA levels, and adjuvant treatments were systematically evaluated. In our study involving 220 patients, 138 were male (62.7%), with a median age of 62 years and a median body mass index (BMI) of 25.1 kg/m². In the patient group without risk factors, no statistically significant difference was detected in DFS rates between those who received treatment and those who did not (p=0.546). DFS rates of patients with >1 risk factor were found to be statistically significantly lower than those with a single risk factor (p=0.017). In patients with >1 risk factor, the DFS of those who did not receive adjuvant treatment was significantly lower than those who received adjuvant treatment (p<0.001). In the patient group with recurrence, when adjuvant treatments were considered, recurrence was observed to be significantly higher in the group receiving capecitabine (p=0.01). The decision for adjuvant chemotherapy in stage IIA colon cancer patients involves careful consideration of various parameters and risk factors. The evolving landscape of research may refine recommendations, ensuring optimal treatment outcomes while minimizing unnecessary toxicity.

Informations de copyright

S. Karger AG, Basel.